Savara Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Austin, TX USA
Total Funding:$80M
Industry:Pharma
Founded:2007
Lead Investor(s):Jefferies LLCS

Estimated Revenue & Financials

  • Savara's estimated annual revenue is currently $12.5M per year.
  • Savara received $47.0M in venture funding in October 2017.
  • Savara's estimated revenue per employee is $201,000
  • Savara's total funding is $80M.

Employee Data

  • Savara has 62 Employees.
  • Savara grew their employee count by 24% last year.
  • Savara currently has 3 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
Redmond and Gre...
$15.1M7519%N/A-N/A
Galderma Labora...
$53.3M265N/AN/A-N/A
Empower Pharmac...
$27.7M13828%N/A-N/A
Unicon Pharma
$14.1M706%N/A-N/A
ION
$25.5M1272%N/A-N/A
QuVa Pharma
$111.4M55412%N/A-N/A
Vetoquinol USA
$30.4M151N/AN/A-N/A
Lexicon Pharmac...
N/A354N/AN/A-N/A
IntrinsiQ
$22.5M112N/AN/A-N/A
ULURU Inc.
N/A27N/AN/A-N/A
Missing a competitor? Contribute!?
Submit

Savara Inc. is an orphan lung disease company. Savara's pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara's strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma)

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

62

Number of Employees

$12.5M

Revenue (est)

3

Current Jobs

24%

Employee Growth %

$80M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Savara News

09/03/2019 - Head-To-Head Comparison: Concert Pharmaceuticals (NASDAQ:CNCE) versus Savara (NASDAQ:SVRA)

Concert Pharmaceuticals (NASDAQ:CNCE) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better ...

09/08/2019 - GSA Capital Partners LLP Purchases Shares of 86,888 Savara Inc (NASDAQ:SVRA)

GSA Capital Partners LLP purchased a new stake in Savara Inc (NASDAQ:SVRA) in the 2nd quarter, according to the company in its most ...

09/03/2019 - Contrasting Savara (NASDAQ:SVRA) and Galectin Therapeutics (NASDAQ:GALT)

Savara (NASDAQ:SVRA) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better business?

Savara Funding

DateAmountRoundLead InvestorsReference
2009-06-11$0.8MAArticle
2012-06-13$8.6MBThe Keiretsu ForumArticle
2013-03-21$16.0MBTech Coast AngelsArticle
2014-06-13$4.5MUndisclosedArticle
2014-10-07$10.0MUndisclosedArticle
2015-12-22$18.5MUndisclosedArticle
2016-03-02$20.0MCArticle
2017-05-02$15.0MUndisclosedSilicon Valley BankArticle
2017-06-05$46.0MUndisclosedJefferies LLCSArticle
2017-10-30$47.0MUndisclosedArticle

Savara Executive Hires

DateNameTitleReference
2016-11-03David LowranceCFOArticle

Savara Acquisitions

DateCompany NameAmountNotesReference
2017-04-28Mast Therapeutics, Inc.Article